(Reuters) -Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company’s domestic production network.

The Cambridge-based company plans to invest more than $140 million to add the final manufacturing step to its existing facility in Massachusetts.

The move will support both commercial and clinical supply as the company seeks to reduce reliance on contract manufacturers.

Construction has begun at the Moderna Technology Center in Norwood, with the company targeting completion by the first half of 2027. The expansion is expected to create hundreds of skilled biomanufacturing jobs.

“By onshoring drug product manufacturing to our campus in Norwood, Massachusetts, we have completed the full

See Full Page